Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

posoleucel

A population of closely human leukocyte antigen (HLA)-matched, off-the-shelf (OTS), donor-derived cytotoxic T lymphocytes (CTLs) that are specifically reactive towards six viruses, Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), human herpesvirus 6 (HHV6; HHV-6), human polyomavirus type I (BKV) and human polyomavirus type II (JC virus; JCV), with potential antiviral activity. Upon infusion into allogeneic hematopoietic stem cell transplant (HSCT) recipients and immunocompromised patients, posoleucel provides virus-specific cellular immunity and causes specific anti-viral effects against active viral infections. This may prevent EBV, CMV, AdV, HHV6, BKV and JCV reactivation and infection, and inhibits viral-associated diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic EBV/CMV/AdV/HHV6/BKV/JCV-specific CTLs ALVR105
allogeneic multi-virus-specific CTLs ALVR105
allogeneic multi-virus-specific cytotoxic T lymphocytes ALVR105
VSTs ALVR105
US brand name:Viralym-M
Code name:ALVR 105
ALVR-105
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search